Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology

Degenerative cervical myelopathy represents a prevalent and highly disabling form of non-traumatic spinal cord injury that typically follows a progressive trajectory if left untreated. Conventional clinical management has historically relied on a reactive approach, often delaying diagnosis and surgical intervention until substantial functional impairment and permanent neurological damage have already occurred. To overcome these limitations, modern diagnostic strategies increasingly incorporate multimodal assessments such as quantitative magnetic resonance imaging, advanced neurophysiological evaluations, and precise sensor-based gait metrics to identify subtle neurodegeneration before overt disability arises. Furthermore, analyzing biomarkers of microstructural damage and adaptive neuroplasticity helps clinicians better stratify patient risk and predict long-term functional outcomes. Ultimately, shifting from reactive care toward early detection and proactive management aims to preserve neurological function, optimize therapeutic timing, and prevent severe long-term disability in affected individuals.https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00314-5/fulltext

The ROAM/EORTC-1308 clinical trial investigated the effectiveness of adjuvant radiotherapy compared to observation following the complete surgical removal of WHO grade 2 atypical meningiomas. By analyzing 157 patients across 11 countries, researchers discovered that early radiation treatment significantly improved disease-free survival and cut the risk of tumor recurrence in half over a median follow-up of 64 months. Although patients receiving radiotherapy experienced manageable, mild-to-moderate adverse events such as fatigue and hair loss, overall survival rates and health-related quality of life remained comparable between both groups. Furthermore, exploratory molecular analyses confirmed that the benefits of radiation therapy persisted independently of the tumor's intrinsic methylation class or integrated risk score. Ultimately, this international study provides robust, high-quality evidence suggesting that adjuvant radiotherapy should be strongly considered to prevent relapses in patients with completely resected atypical meningiomas.

These clinical guidelines from the European Academy of Neurology and the European Society of Clinical Microbiology and Infectious Diseases provide evidence-based recommendations for diagnosing and managing infectious encephalitis in adults. The publication addresses critical challenges, highlighting the importance of timely intravenous aciclovir treatment and the careful interpretation of diagnostic tools such as lumbar punctures, cerebrospinal fluid testing, and neuroimaging. Furthermore, the guidelines outline strategies for additional investigations, antiviral therapy durations, and the implementation of structured intensive care and rehabilitation. Ultimately, the authors emphasize the necessity of multidisciplinary care to mitigate the severe morbidity and mortality associated with this neurological emergency.

Cerebral amyloid angiopathy is a condition characterized by protein buildup in the walls of small brain vessels, making them brittle and prone to spontaneous lobar bleeding and cognitive decline. Diagnosis relies heavily on specialized magnetic resonance imaging to detect superficial hemorrhages and white matter changes while carefully excluding deep brain bleeds associated with hypertension. Clinical management requires a balanced approach, particularly when determining whether to use antithrombotic medications by weighing the risk of stroke against the likelihood of recurrent hemorrhages. Furthermore, the disease can manifest in distinct presentations, including neurodegenerative decline or autoimmune inflammation, which requires targeted immunosuppressive therapy. Clinicians must also remain vigilant for mimics such as primary central nervous system lymphoma or identify rare causes in younger individuals through detailed surgical and family histories.This episode is based on a paper written exclusively for the Weekly Neurology Deep Dive Podcast by Amer A. Ghavanini MD PhD FRCPC.

An international expert panel utilized a modified Delphi process to establish practical consensus recommendations for assessing, monitoring, and managing brentuximab vedotin-induced peripheral neuropathy in patients with lymphoma. The resulting guidelines emphasize comprehensive baseline risk profiling, routine evaluation using validated tools like the Total Neuropathy Score, and prompt intervention for escalating symptoms to minimize nerve damage. Additionally, the study highlights the importance of personalized dose modifications, shared decision-making, and multidisciplinary support—including physical therapy and psychological care—to preserve patients' overall quality of life while maintaining therapeutic efficacy.

The reviewed literature examines the neurological complications associated with various tick-transmitted infections across North America and Eurasia. Although many tick-borne illnesses produce generalized, non-specific symptoms, certain pathogens possess the ability to breach the blood-brain barrier and cause true neuroinvasive disease. Specifically, infections such as Lyme disease, human monocytic ehrlichiosis, and Borrelia miyamotoi can occasionally result in meningitis or peripheral nerve involvement. Conversely, viral pathogens like Powassan virus and tick-borne encephalitis virus frequently trigger severe encephalitis and carry a high risk of long-term neurological impairment. Ultimately, the publication highlights the critical differences between systemic inflammation, common headaches, and genuine central nervous system infections to improve clinical diagnosis and management.

Monoclonal gammopathy of clinical significance (MGCS) is an overarching classification for non-malignant disorders directly caused by monoclonal proteins produced during clonal plasma cell proliferative disorders. These conditions encompass organ-specific diseases affecting the renal, neurological, cutaneous, and ocular systems, as well as complex multi-system syndromes like POEMS and Schnitzler syndrome. Because diagnosis often requires establishing a precise causal link between the protein and organ damage, clinicians must carefully differentiate true MGCS from coincidental associations. Management strategies typically focus on eradicating the underlying pathogenic clone or limiting the detrimental effects of the monoclonal proteins to halt disease progression.

Canada achieved nationwide implementation of newborn screening for spinal muscular atrophy in August 2024, establishing a standardized public health approach across all provinces and territories. A cross-sectional survey of provincial laboratory directors evaluated over 1.5 million screened infants to determine national birth prevalence and catalog testing methodologies. The calculated birth prevalence for the condition stood at approximately 1 in 12,524 live births, with survival motor neuron 2 gene copy numbers aligning closely with international proportions. Despite universal screening implementation, significant interprovincial variability persists regarding laboratory testing protocols, reporting practices, and the timing of results availability during initial family contact. Furthermore, inequities remain in the regional reimbursement of disease-modifying therapies, particularly affecting newborns diagnosed with four copies of the modifier gene despite growing expert consensus favoring early treatment.

POEMS syndrome is a life-threatening, multi-system disorder driven by an underlying plasma cell neoplasm, characterized by mandatory major criteria such as polyneuropathy and a clonal plasma cell disorder. Diagnosis requires a careful combination of clinical evaluations, radiographic bone assessments, bone marrow biopsies, and elevated vascular endothelial growth factor (VEGF) levels. Because the condition's pathogenesis remains poorly understood, risk stratification relies primarily on the patient's clinical phenotype and specific prognostic indicators like age and renal function. Treatment strategies are generally risk-adapted, utilizing localized irradiation for dominant solitary plasmacytomas or systemic therapy—such as alkylator-based regimens, immunomodulatory drugs, and autologous stem cell transplantation—for disseminated bone marrow involvement. Emphasizing prompt recognition, supportive care, and clone-directed therapies yields the best outcomes for patients managing this complex and rare syndrome.

Two phase 3 clinical trials evaluated the efficacy and safety of oveporexton, an oral orexin receptor 2-selective agonist, for treating narcolepsy type 1 over a 12-week period. Participants receiving twice-daily oveporexton experienced significant improvements in mean sleep latency, excessive daytime sleepiness, and the weekly cataplexy rate compared to those on a placebo. While adverse events such as increased urinary frequency and transient insomnia were more common in the treatment groups, most side effects were mild to moderate in severity. These findings confirm that addressing the underlying orexin deficiency successfully alleviates core narcolepsy symptoms and enhances overall quality of life.